Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the net profit margin high or low?
The net profit margin of -648.32% is 39% below its 1-year average of -466.74%, around the middle of its 1-year range (-1595.98%–0.00%).
38.90% below its 12-month average of -466.74%.
Reported quarterly profit margin; no daily interpolation. Q3 FY2026 (2026-06-30): -597.40%.
NET PROFIT MARGIN
-648.32%
NET PROFIT MARGIN AVG TTM
-466.74%
NET PROFIT MARGIN AVG 3Y
0.00%
NET PROFIT MARGIN AVG 5Y
N/A
NET PROFIT MARGIN AVG 10Y
N/A
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-38.90%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-0.35%
median of 862 covered companies
CURRENT VS SECTOR MEDIAN
-185134.29%
vs the sector median at left
Citius Oncology, Inc.
Market Cap
$79.03M
Net Profit Margin
-648.32%
TTM Avg
-466.74%
3Y Avg
0.00%
5Y Avg
N/A
Market Cap
$78.59M
Net Profit Margin
-12.91%
TTM Avg
-907.67%
3Y Avg
-691.25%
5Y Avg
-536.96%
Market Cap
$79.61M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$78.29M
Net Profit Margin
-47475.71%
TTM Avg
-41070.98%
3Y Avg
-27618.26%
5Y Avg
-38759.83%
Market Cap
$78.07M
Net Profit Margin
-130000.00%
TTM Avg
-89627.13%
3Y Avg
-49555.20%
5Y Avg
-36262.68%
Market Cap
$80.30M
Net Profit Margin
-4560.82%
TTM Avg
-1001.79%
3Y Avg
-692.03%
5Y Avg
-1554.36%
Market Cap
$77.54M
Net Profit Margin
-155404.38%
TTM Avg
-155404.38%
3Y Avg
-155404.38%
5Y Avg
-155404.38%
Market Cap
$81.20M
Net Profit Margin
-430.43%
TTM Avg
-446.97%
3Y Avg
-347.08%
5Y Avg
-386.84%
Market Cap
$81.22M
Net Profit Margin
-1168.20%
TTM Avg
-1464.39%
3Y Avg
-946.48%
5Y Avg
-672.82%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Citius Oncology, Inc. (CTOR) | $79.03M | -648.32% | -466.74% | 0.00% | N/A |
| vTv Therapeutics Inc. (VTVT)vs › | $78.59M | -12.91% | -907.67% | -691.25% | -536.96% |
| Acrivon Therapeutics, Inc. Common Stock (ACRV)vs › | $79.61M | 0.00% | 0.00% | 0.00% | 0.00% |
| Sera Prognostics, Inc. (SERA)vs › | $78.29M | -47475.71% | -41070.98% | -27618.26% | -38759.83% |
| Inovio Pharmaceuticals, Inc. (INO)vs › | $78.07M | -130000.00% | -89627.13% | -49555.20% | -36262.68% |
| Humacyte, Inc. (HUMA)vs › | $80.30M | -4560.82% | -1001.79% | -692.03% | -1554.36% |
| Neonc Technologies Holdings, Inc. (NTHI)vs › | $77.54M | -155404.38% | -155404.38% | -155404.38% | -155404.38% |
| Nutriband Inc. (NTRB)vs › | $81.20M | -430.43% | -446.97% | -347.08% | -386.84% |
| MediciNova, Inc. (MNOV)vs › | $81.22M | -1168.20% | -1464.39% | -946.48% | -672.82% |
| Outset Medical, Inc. (OM)vs › | $76.74M | -63.06% | -90.45% | -113.67% | -137.76% |
Operating Margin
0.0%
Net Profit Margin
-648.3%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | -597.40% |
| 2026-03-31 | -1595.98% |
| 2025-12-31 | -140.31% |
| 2025-09-30 | 0.00% |
| 2025-06-30 | 0.00% |
| 2025-03-31 | 0.00% |
| 2024-12-31 | 0.00% |
| 2024-09-30 | 0.00% |
| 2024-06-30 | 0.00% |
| 2024-03-31 | 0.00% |
| 2023-12-31 | 0.00% |
| 2023-09-30 | 0.00% |
| 2023-06-30 | 0.00% |
| 2023-03-31 | 0.00% |
| 2022-12-31 | 0.00% |
| 2022-09-30 | 0.00% |
| 2022-06-30 | 0.00% |
